Ophthalmologists Discuss Important Topics in Vitreoretina

At PIE Magazine, we’re sometimes known as the “shock jocks” of ophthalmic publishing — thanks to our funky style (in both fashion and medical reporting). So, we decided to try on those radio show shoes, with a segment of our own: the PIE Radio Show.

We asked renowned surgeons from around the world to chime in on some of the most important topics in ophthalmology today — from COVID-19’s impacts, to business decisions and innovations in medical and surgical retina. So, sit back, relax and don’t touch that dial . . . the PIE Radio Show is ON AIR!

Read More
Ophthalmologists Discuss Important Topics in Vitreoretina

A Lowdown on the Link between Conjunctivitis and COVID-19

In the light of the current COVID-19 situation, diagnosing the pink eye or conjunctivitis has now an added dimension of caution. The alert came about after anecdotal sources and researchers raised the alarm about “the possibility of eye infection and the ocular route as a potential infection source.

This and several other reports prompted the American Academy of Ophthalmology (AAO) to issue guidelines, which included warnings that “the virus can cause conjunctivitis and possibly be transmitted by aerosol contact with conjunctiva.”

The circumstances of its infection mode have put ophthalmologists around the globe on the frontline, and it has been especially poignant ever since the passing of Dr. Li Wenliang, the ophthalmologist from Wuhan who warned of the virus in December 2019. It was believed that he contracted the novel coronavirus from a glaucoma patient.

Read More
A Lowdown on the Link between Conjunctivitis and COVID-19

A New Era in the Treatment of Hereditary Optic Neuropathies

Should these treatments prove to be effective and safe, they will radically transform the treatment approach to patients at risk of visual loss. Gene therapies are emerging for several inherited retinal diseases as well. These recent scientific and clinical developments may represent the beginning of an era of approved gene therapies for a wider range of neurologic diseases.

Retinal degenerative diseases are a leading cause of irreversible blindness. The central pathology in many of these conditions is retinal death, induced by a mix of genetic and environmental factors. Inherited conditions are increasingly recognized as an important component of the neuro-ophthalmic differential diagnosis of sub-acute vision loss. For these blinding conditions, innovations in gene and cell therapy approaches offer therapeutic intervention at various disease stages.

A recent review by Dr. Tatiana Bakaeva et.al from Harvard Medical School, Boston sheds light on hereditary optic neuropathies.

Read More
A New Era in the Treatment of Hereditary Optic Neuropathies

Oasis EyeQ – The Official Newsletter of OasisEye Specialists

Oasis EyeQ Newsletter (June Edition)

Cataracts remain the leading cause of vision loss worldwide. Cataracts are cloudy areas that form in the lens, which is normally transparent. They are the main cause of vision loss in people aged over 40 years, so it seems fitting that an entire month should be dedicated to education and awareness.

Stay up to date by subscribing to the Oasis EyeQ newsletter. Find out about all the latest topics, news and events.

Beovu: What’s the latest with the ophthalmic community’s concerns?

Reports and opinions keep pouring in about Novartis’ Beovu® (brolucizumab), meant to treat wet or neovascular age-related macular degeneration (nAMD). In February, the American Society of Retina Specialists (ASRS) noted a risk of intraocular inflammation and retinal vasculitis associated with the drug; more concerning was that 11 of the 14 cases of vasculitis were occlusive retinal vasculitis, which can lead to vision loss. The drug’s main appeal is that it reduces the rate of injection to once a quarter following the initiation of treatment.

Novartis backed these findings in April, noting a “confirmed safety signal of rare adverse events of retinal vasculitis and/ or retinal vascular occlusion that may result in severe vision loss.” Novartis’ safety review committee (SRC) noted a 3.3% rate of retinal vasculitis in study patients who had been treated with Beovu. Most of the patients (74%) experienced symptoms within six months of the treatment, though some (12%) experienced it as late as 12-18 months afterwards. According to an ASRS report, the earlier events were associated more frequently with moderate or severe vision loss.

Read More
Beovu: What’s the latest with the ophthalmic community’s concerns?

B40 Group Charity Eye Cataract Surgery – Patient Testimonial

“Saya telah menghidap kencing manis selama 10 tahun dan ia membuatkan saya tidak berapa jelas untuk melihat. Selepas melakukan kan pembedahan saya berasa begitu lega kerana dapat melihat dengan lebih jelas. Saya amat berterima kasih kepada pihak OasisEye Specialists dan Dr Vanitha yang telah menjalankan pembedahan dengan jayanya kepada kedua-dua belah mata saya.”

Fatimah Binti Yeop Mokhtar

Pesakit B40

72 Tahun

Katarak- Pembedahan Kedua-dua Mata

B40 Group Charity Eye Cataract Surgery – Patient Testimonial

“Pembedahan katarak ini tidak menyakitkan dan sangat mudah. Saya pasti akan mengesyorkan OasisEye Specialists kepada sesiapa yang bertanyakan kepada saya tentang pembedahan katarak, dan saya bersyukur atas peluang untuk melakukan pembedahan ini. Prosedur di sini begitu pantas dan cekap. Terima kasih kepada Dr Tai Lai Yong dan semua staf OasisEye Specialists atas peluang ini.”

Zainuddin Bin Mat Nor

Pesakit B40

77 Tahun

Katarak- Pembedahan Mata Kiri

B40 Group Charity Eye Cataract Surgery – Patient Testimonial

“Saya tak dapat nak terangkan dengan kata-kata betapa terujanya saya apabila saya dapat melihat dengan lebih jelas sekarang. Selepas sahaja Dr Kenneth memberitahu saya bahawa mereka ingin menjalankan pembedahan, saya berasa begitu gembira dan saya merasakan ini adalah peluang yang terbaik terutamanya apabila umur saya semakin meningkat. Terima kasih Dr Kenneth Fong dan staf OasisEye Specialists atas perkhidmatan yang baik.”

Mohd Hassan Bin Mohd Tahir

Pesakit B40

62 Tahun

Selaput Luar Mata- Pembedahan Mata Kanan

B40 Group Charity Eye Cataract Surgery – Patient Testimonial

“Terima kasih Dr Wong Hon Seng dan staf OasisEye yang menyediakan rawatan yang menakjubkan. Saya bersyukur atas peluang yang diberikan kepada saya. Mereka sangat baik hati dan megambil sepenuh perhatian sepanjang prosedur pembedahan mata saya. Terima kasih atas perkhidmatan yang disediakan, saya mempunyai penglihatan yang lebih baik sekarang.”

Anjang Binti Hashim

Pesakit B40

80 Tahun

Katarak- Pembedahan pada mata kanan

Retinopathy of Prematurity

What is retinopathy of prematurity?

Retinopathy of prematurity (ROP) occurs in infants who are born prematurely, where blood vessels in the retina do not form normally. The retina is a thin sheet of nerves lining the back wall of the eye and functions like the film in a conventional camera. ROP can consequently cause serious problems affecting a child’s eyes and vision.

What causes retinopathy of prematurity?

The blood vessels of the retina begin to form around the 3rd month of gestation. These vessels are fully developed by the time the baby is born at full-term. However, if the baby is born earlier than expected, this process may be incomplete. The extent usually depends on the gestational age and weight at the time of delivery.  The developing retinal vessels are fragile and can easily leak and bleed within the eye. Consequently, scar tissue may develop and pull the retina away from the inner wall of the eye, causing a retinal detachment. In severe cases this can result in complete loss of vision.

What are the risk factors for retinopathy of prematurity?

In general, babies born before 32 weeks of gestation or who weigh less than 1500 grams at birth are screened for the condition. Even if a baby is born later than 32 weeks of gestation, if they are deemed to be high-risk by your doctor, they may also be recommended to have an eye examination.

The rate of ROP has declined significantly in developed countries due to improved care in neonatal intensive care units. This improvement in care also means that more babies born very early are now able to survive and therefore have a significant risk for developing ROP.

What are the symptoms of retinopathy of prematurity?

Your baby will not be aware of any early changes related to ROP neither are these changes visible with the naked eye. Only an eye examination by an ophthalmologist will reveal any abnormalities.

There are five stages of ROP, with the mildest being Stage 1 and implying minimal vessel growth abnormality. Stage 5 is the most extreme form where the infant suffers from a retinal detachment and extensive scarring in the eye. If not picked up in a timely fashion, children with ROP may develop abnormal eye movements, squints (cross-eyed) and white-looking pupils (known as leukocoria).

What investigations are required for ROP?

Any premature infant or new-born deemed to be at high-risk will need to be screened. Usually, the first exam should be within a few weeks of birth, depending on the baby’s gestational age. The interval for repeat examinations thereafter depends on what your eye doctors finds and how your child is developing in general.

In the long-term, all premature children require at least an annual eye check with or without a dilated fundoscopy (retinal examination). This is to ensure their vision is developing as it should as there is a higher incidence of myopia (short-sightedness) in these children.

 How is ROP treated?

Treatment is tailored to each individual infant. As with most things, timely intervention usually provides better outcomes but sometimes in spite of this, ROP will still progress as it is a challenging condition to manage. Some infants with the extreme form of the condition will require urgent treatment which may involve laser, intravitreal injections or even eye surgery.

Laser therapy (photocoagulation) involves shining a bright coherent beam of light into the eye to ablate abnormal tissue. This helps to halt the progression of abnormal blood vessels and is usually performed to prevent retinal bleeding, scarring or detachment.

An intravitreal injection of a medication called an anti-VEGF (anti-vascular endothelial growth factor) is sometimes required to help counteract the chemical factors that cause abnormal vessel growth. This injection usually lasts around month and may be required more than once.

If the ROP is more advanced then surgery may be indicated especially if the retina detached. In general, intervention is preferable before this stage as the outlook for vision is uncertain once the retina detaches.

What are the long-term implications of ROP?

Many infants with ROP might also suffer from other development problems related to prematurity, and may need treatment accordingly.

Advanced ROP can lead to significant visual loss or blindness. Almost 1 in 10 babies with initially mild forms can progress to have severe visual impairment. Early diagnosis and treatment is, therefore, vital in preventing advanced disease. Even if there was no ROP detected, premature babies require lifelong follow-up to ensure their vision is developing as it should be.